Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...

today announced that it has concluded dosing of Cohort A patients in the ACHIEVE Phase 2B UK clinical trial. The available data show a favorable safety and efficacy response in Cohort A patients ...

today announced the first Cohort B patient in the ACHIEVE Phase 2B UK clinical trial, evaluating TCB008 in Acute Myeloid Leukemia, has completed the full dosing regiment. The ACHIEVE trial is an ...

The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in the treatment of acute myeloid leukemia using ...

Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers - Company remains on track to report Phase 1a ...

Alzamend Neuro developed a head coil for high-resolution brain imaging in Phase 2 trials, aiming to optimize lithium dosing ...

Chemomab Therapeutics (CMMB) announced the successful completion of its End-of-Phase 2 Meeting with the FDA and alignment with FDA on the ...

Vetigenics is seeing encouraging results of a completed study for an antibody aimed at treating oral melanoma in dogs, used ...

today announced it has completed enrollment of all four multiple-ascending dose (MAD) cohorts for the Phase 1 clinical trial of SAT-3247 in healthy volunteers. “The completion of healthy ...

The initial Cohort B patient has completed the dosing regiment ... The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line ...

To date, the analyses suggest that TTX-MC138 demonstrates a PK/PD profile consistent with preclinical results and results from TransCode's previous Phase 0 clinical trial. Specifically ...